{"id":"tizanidine","rwe":[],"_fda":{"id":"95820c11-e6e2-4f26-6af9-2cc60ef94c41","set_id":"01c0d3d3-2373-a1b7-822a-80a66291a248","openfda":{"upc":["0360505025237"],"unii":["B53E3NMY5C"],"route":["ORAL"],"rxcui":["313412","313413"],"spl_id":["95820c11-e6e2-4f26-6af9-2cc60ef94c41"],"brand_name":["tizanidine"],"spl_set_id":["01c0d3d3-2373-a1b7-822a-80a66291a248"],"package_ndc":["60505-0251-1","60505-0251-3","60505-0251-2","60505-0252-1","60505-0252-3","60505-0252-2"],"product_ndc":["60505-0251","60505-0252"],"generic_name":["TIZANIDINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["TIZANIDINE HYDROCHLORIDE"],"manufacturer_name":["Apotex Corp."],"application_number":["ANDA076533"],"is_original_packager":[true]},"version":"14","overdosage":["10 OVERDOSAGE A review of the safety surveillance database revealed cases of intentional and accidental tizanidine overdose. Some of the cases resulted in fatality and many of the intentional overdoses were with multiple drugs, including CNS depressants. The clinical manifestations of tizanidine overdose were consistent with its known pharmacology. In the majority of cases, a decrease in sensorium was observed including lethargy, somnolence, confusion, and coma. Depressed cardiac function is also observed including most often bradycardia and hypotension. Respiratory depression is another common feature of tizanidine overdose. Should overdose occur, ensure the adequacy of an airway and monitor cardiovascular and respiratory function. Dialysis is not likely to be an efficient method of removing tizanidine from the body [see Description ( 11 )] . In general, symptoms resolve within one to three days following discontinuation of tizanidine and administration of appropriate therapy. Because of the similar mechanism of action, symptoms and management of tizanidine overdose are similar to that following clonidine overdose. For the most recent information concerning the management of overdose, contact a poison control center."],"description":["11 DESCRIPTION Tizanidine Tablets, USP contains tizanidine hydrochloride as the active ingredient, which is a central alpha 2 -adrenergic agonist. Its chemical name is 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiodiazole monohydrochloride. It has a molecular formula of C 9 H 8 CIN 5 S·HCl and a molecular weight of 290.17. Its structural formula is: Tizanidine hydrochloride is almost white to slightly yellow, crystalline powder, which is odorless or with a faint characteristic odor. Tizanidine hydrochloride is slightly soluble in water and methanol; solubility in water decreases as the pH increases. Tizanidine Tablets, USP are for oral administration and contain active ingredient, tizanidine hydrochloride (2.288 mg equivalent to 2 mg tizanidine base, and 4.576 mg equivalent to 4 mg tizanidine base), and the inactive ingredients, anhydrous lactose, colloidal silicon dioxide, microcrystalline cellulose and stearic acid. Meets USP Dissolution Test 2"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Tizanidine Tablets, USP 2 mg are available for oral administration as white to off-white, round, scored tablets, imprinted “APO” over “TI-2” on one side and plain with a bisect score on the other side. They are supplied as follows: Bottles of 100 (NDC 60505-0251-1) Bottles of 150 (NDC 60505-0251-3) Bottles of 1,000 (NDC 60505-0251-2) Tizanidine Tablets, USP 4 mg are available for oral administration as white to off-white, round, scored tablets, imprinted “APO” over “TI-4” on one side and plain with a quadrisect score on the other side. They are supplied as follows: Bottles of 100 (NDC 60505-0252-1) Bottles of 150 (NDC 60505-0252-3) Bottles of 1,000 (NDC 60505-0252-2) 16.2 Storage and Handling Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container [see USP]."],"effective_time":"20250311","clinical_studies":["14 CLINICAL STUDIES The efficacy of tizanidine for the treatment of spasticity was demonstrated in two adequate and well-controlled studies in patients with multiple sclerosis or spinal cord injury (Studies 1 and 2). Single-Dose Study in Patients with Multiple Sclerosis with Spasticity In Study 1,140 patients with spasticity caused by multiple sclerosis were randomized to receive single oral doses of 8 mg or 16 mg of tizanidine, or placebo. Patients and assessors were blinded to treatment assignment and efforts were made to reduce the likelihood that assessors would become aware indirectly of treatment assignment (e.g., they did not provide direct care to patients and were prohibited from asking questions about side effects). Response was assessed by physical examination; muscle tone was rated on a 5-point scale (Ashworth score) as follows: 0 = normal muscle tone 1 = slight spastic catch 2 = more marked muscle resistance 3 = considerable increase in tone, making passive movement difficult 4 = a muscle immobilized by spasticity Spasm counts were also collected. Assessments were made at 1, 2, 3 and 6 hours after treatment. A statistically significant reduction of the Ashworth score for tizanidine compared to placebo was detected at 1, 2, and 3 hours after treatment. Figure 2 below shows a comparison of the mean change in muscle tone from baseline as measured by the Ashworth scale. The greatest reduction in muscle tone was 1 to 2 hours after treatment. By 6 hours after treatment, muscle tone in the 8 mg and 16 mg tizanidine groups was indistinguishable from muscle tone in patients who received placebo. Within a given patient, improvement in muscle tone was correlated with plasma concentration. Plasma concentrations were variable from patient to patient at a given dose. Although 16 mg produced a larger effect, adverse reactions including hypotension were more common and more severe than in the 8 mg group. There were no differences in the number of spasms occurring in each group. Figure 2: Single Dose Study—Mean Change in Muscle Tone from Baseline as Measured by the Ashworth Scale ± 95% Confidence Interval (A Negative Ashworth Score Signifies an Improvement in Muscle Tone from Baseline) Seven-Week Study in Patients with Spinal Cord Injury with Spasticity In a 7-week study (Study 2), 118 patients with spasticity secondary to spinal cord injury were randomized to either placebo or tizanidine. Steps similar to those taken in the first study were employed to ensure the integrity of blinding. Patients were titrated over 3 weeks up to a maximum tolerated dose or 36 mg daily given in three unequal doses (e.g., 10 mg given in the morning and afternoon and 16 mg given at night). Patients were then maintained on their maximally tolerated dose for 4 additional weeks (i.e., maintenance phase). Throughout the maintenance phase, muscle tone was assessed on the Ashworth scale within a period of 2.5 hours following either the morning or afternoon dose. The number of daytime spasms was recorded daily by patients. At endpoint (the protocol-specified time of outcome assessment), there was a statistically significant reduction in muscle tone and frequency of spasms in the tizanidine treated group compared to placebo. The reduction in muscle tone was not associated with a reduction in muscle strength (a desirable outcome), but also did not lead to any consistent advantage of tizanidine treated patients on measures of activities of daily living. Figure 3 below shows a comparison of the mean change in muscle tone from baseline as measured by the Ashworth scale. Figure 3: Seven Week Study—Mean Change in Muscle Tone 0.5 to 2.5 Hours After Dosing as Measured by the Ashworth Scale ± 95% Confidence Interval (A Negative Ashworth Score Signifies an Improvement in Muscle Tone from Baseline)"],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in other sections of the prescribing information: • Hypotension [see Warnings and Precautions ( 5.1 )] • Liver Injury [see Warnings and Precautions ( 5.2 )] • Sedation [see Warnings and Precautions ( 5.3 )] • Hallucinosis/Psychotic-Like Symptoms [see Warnings and Precautions ( 5.4 )] • Hypersensitivity Reactions [see Warnings and Precautions ( 5.5 )] • Withdrawal Adverse Reactions [ see Warnings and Precautions ( 5.6 )] The most common adverse reactions (greater than 10% of patients taking tizanidine and greater than in patients taking placebo) were dry mouth, somnolence, asthenia, and dizziness. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. The safety of tizanidine has been evaluated in three double-blind, randomized, placebo-controlled clinical studies [see Clinical Studies ( 14 )] . Two studies were conducted in patients with multiple sclerosis and one in patients with spinal cord injury. Each study had a 13-week active treatment period which included a 3-week titration phase to the maximum tolerated dose up to 36 mg/day in three divided doses, a 9-week plateau phase where the dose of tizanidine was held constant and a 1-week dose tapering period. In all, 264 patients received tizanidine and 261 patients received placebo. Across the three studies approximately 51% of patients were women, and the median dose during the plateau phase ranged from 20 to 28 mg/day. The most common adverse reactions (>10% of patients treated with tizanidine) reported in multiple dose, placebo-controlled clinical studies involving 264 patients with spasticity were dry mouth, somnolence/sedation, asthenia (weakness, fatigue and/or tiredness), and dizziness. Three-quarters of the patients rated the reactions as mild to moderate and one-quarter of the patients rated the reactions as being severe. These adverse reactions appeared to be dose related. Table 1 lists adverse reactions that were reported in greater than 2% of patients in three multiple dose, placebo-controlled studies who received tizanidine where the frequency in the tizanidine group was greater than the placebo group. Table 1: Multiple Dose, Placebo-Controlled Studies—Adverse Reactions Reported in >2% of Patients Treated with Tizanidine Tablets and Incidence Greater than Placebo Adverse Reaction Placebo N = 261 % Tizanidine Tablet N = 264 % Dry mouth 10 49 Somnolence 10 48 Asthenia 16 41 Dizziness 4 16 UTI 7 10 Infection 5 6 Liver test abnormality 2 6 Constipation 1 4 Vomiting 0 3 Speech disorder 0 3 Amblyopia (blurred vision) <1 3 Urinary frequency 2 3 Flu syndrome 2 3 Dyskinesia 0 3 Nervousness <1 3 Pharyngitis 1 3 Rhinitis 2 3 *includes weakness, fatigue, and/or tiredness In the single dose, placebo-controlled study involving 142 patients with spasticity due to multiple sclerosis (Study 1) [see Clinical Studies ( 14 )] , the patients were specifically asked if they had experienced any of the four most common adverse reactions: dry mouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness), and dizziness. In addition, hypotension and bradycardia were observed. The occurrence of these reactions is summarized in Table 2. Other events were, in general, reported at a rate of 2% or less. Table 2: Single Dose, Placebo-Controlled Study—Common Adverse Reactions Reported Adverse Reaction Placebo N = 48 % Tizanidine Tablet, 8mg, N = 45 % Tizanidine Tablet, 16 mg, N = 49 % Somnolence 31 78 92 Dry mouth 35 76 88 Asthenia 40 67 78 Dizziness 4 22 45 Hypotension 0 16 33 Bradycardia 0 2 10 *includes weakness, fatigue, and/or tiredness 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of tizanidine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiac Disorders: Ventricular tachycardia, decreased blood pressure Hepatobiliary Disorders: Hepatotoxicity [see Warnings and Precautions ( 5.2 )] , hepatitis Musculoskeletal and Connective Tissue Disorders: arthralgia Nervous System Disorders: Convulsion, paresthesia, tremor, muscle spasms Psychiatric Disorders: Hallucinations [see Warnings and Precautions ( 5.4 )] , depression Skin and Subcutaneous Tissue Disorders: Stevens Johnson Syndrome, anaphylactic reaction [see Warnings and Precautions ( 5.5 )] , exfoliative dermatitis, rash"],"contraindications":["4 CONTRAINDICATIONS Tizanidine is contraindicated in patients: • taking strong CYP1A2 inhibitors [see Drug Interactions ( 7.1 )]. • with a history of hypersensitivity to tizanidine or the ingredients in tizanidine tablets. Symptoms have included anaphylaxis and angioedema [see Warnings and Precautions ( 5.5 )]. Concomitant use with strong CYP1A2 inhibitors ( 4 , 7.1 ) Patients with a history of hypersensitivity to tizanidine or the ingredients in tizanidine tablets ( 4 , 5.5 )"],"drug_interactions":["7 DRUG INTERACTIONS Moderate or weak CYP1A2 inhibitors: avoid concomitant use; may cause hypotension, bradycardia, or excessive drowsiness; if concomitant use is necessary and adverse reactions occur, reduce tizanidine dosage or discontinue. ( 7.2 , 12.3 ) 7.1 Strong CYP1A2 Inhibitors Concomitant use of tizanidine with strong cytochrome P450 1A2 (CYP1A2) inhibitors (e.g., fluvoxamine, ciprofloxacin) is contraindicated. Changes in pharmacokinetics of tizanidine when administered with a strong CYP1A2 inhibitor resulted in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment [see Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. 7.2 Moderate or Weak CYP1A2 Inhibitors Concomitant use of tizanidine with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. If concomitant use is clinically necessary, and adverse reactions such as hypotension, bradycardia, or excessive drowsiness occur, reduce tizanidine dosage or discontinue tizanidine therapy [see Clinical Pharmacology ( 12.3 )]. 7.3 Oral Contraceptives Concomitant use of tizanidine with oral contraceptives is not recommended. However, if concomitant use is clinically necessary and adverse reactions such as hypotension, bradycardia, or excessive drowsiness occur, reduce or discontinue tizanidine therapy [see Clinical Pharmacology ( 12.3 )]. 7.4 Alcohol and Other CNS Depressants Alcohol increases the exposure of tizanidine after administration of tizanidine. This was associated with an increase in adverse reactions of tizanidine. Concomitant use of tizanidine with CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may cause additive CNS depressant effects, including sedation. Monitor patients who take tizanidine with another CNS depressant for symptoms of excess sedation [see Clinical Pharmacology ( 12.3 )]. 7.5 α 2 -Adrenergic Agonists Concomitant use of tizanidine with other α 2 -adrenergic agonists is not recommended because hypotensive effects may be cumulative [see Warnings and Precautions ( 5.1 )]. 7.6 Antihypertensive Medications Concomitant use of tizanidine tablets with antihypertensive medications may cause additive hypotensive effects [see Warnings and Precautions ( 5.1 ) ] . Monitor patients who take tizanidine tablets with antihypertensive medications for hypotension."],"recent_major_changes":["RECENT MAJOR CHANGES Indications and Usage ( 1 ) 11/2024 Dosage and Administration ( 2.1 , 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) 11/2024 Contraindications ( 4 ) 11/2024 Warnings and Precautions ( 5.1 , 5.2 , 5.4 , 5.5 ) 11/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. 12.2 Pharmacodynamics The CNS depressant effects of tizanidine and alcohol are additive [see Warnings and Precautions ( 5.3 ) and Drug Interactions (7.4)]. 12.3 Pharmacokinetics Tizanidine has linear pharmacokinetics over the doses studied in clinical development [1 mg (half the recommended dosage) to 20 mg]. Tizanidine capsules and tablets are bioequivalent to each other under fasting conditions, but not under fed conditions (see Absorption, Effect of Food). Absorption Following oral administration, tizanidine is essentially completely absorbed. The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism. Effect of Food There are pharmacokinetic differences between tizanidine capsules and tizanidine tablets with respect to administration with food. A single dose of either two 4 mg tablets or two 4 mg capsules was administered under fed and fasting conditions in an open-label, four-period, randomized crossover study in 96 volunteers, of whom 81 were eligible for the statistical analysis. Pharmacokinetics under fed conditions were different than under fasting conditions and vary by dosage form. Tablets or Capsules - Fasting T max was 1 hours after dosing T ½ was approximately 2 hours. Tablets - Fed Mean C max was increased by approximately 30% Median T max was increased by 25 minutes, to 1 hour and 25 minutes. Extent of absorption was increased approximately 30% Capsules - Fed Mean C max was decreased by 20% (consequently, approximately 66% the C max for the tablet when administered with food) Median T max was increased 2 to 3 hours Extent of absorption was increased approximately 10% (consequently, approximately 80% of the amount absorbed from the tablet administered with food) Capsule Content Sprinkled on Applesauce Compared to administration of an intact capsule while fasting: C max and AUC was increased 15% to 20% T max was decreased 15 minutes Figure 1: Mean Tizanidine Concentration vs. Time Profiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers. Tizanidine is approximately 30% bound to plasma proteins. Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%). Approximately 95% of an administered dose is metabolized. The primary cytochrome P450 isoenzyme involved in tizanidine metabolism is CYP1A2. Tizanidine metabolites are not known to be active; their half-lives range from 20 to 40 hours. Excretion Following single and multiple oral dosing of 14 C-tizanidine, an average of 60% and 20% of total radioactivity was recovered in the urine and feces, respectively. Specific Populations Geriatric Patients No specific pharmacokinetic study was conducted to investigate age effects. Cross study comparison of pharmacokinetic data following single dose administration of 6 mg tizanidine showed that younger subjects cleared the drug four times faster than the elderly subjects [see Use in Specific Populations ( 8.5 )]. Patients with Hepatic Impairment The influence of hepatic impairment on the pharmacokinetics of tizanidine has not been evaluated. Because tizanidine is extensively metabolized in the liver, hepatic impairment would be expected to have significant effects on pharmacokinetics of tizanidine [see Use in Specific Populations ( 8.7 )]. Patients with Renal Impairment Tizanidine clearance is reduced by more than 50% in elderly patients with renal insufficiency (creatinine clearance < 25 mL/min) compared to healthy elderly subjects; this would be expected to lead to a longer duration of clinical effect [see Use in Specific Populations ( 8.6 )]. Gender Effects No specific pharmacokinetic study was conducted to investigate gender effects. Retrospective analysis of pharmacokinetic data following single and multiple dose administration of 4 mg tizanidine, however, showed that gender had no effect on the pharmacokinetics of tizanidine. Drug Interactions CYP1A2 Inhibitors The effects of coadministration of fluvoxamine or ciprofloxacin, both strong CYP1A2 inhibitors, on the pharmacokinetics of a single 4 mg dose of tizanidine tablets were studied in 10 healthy subjects. The C max , AUC, and half-life of tizanidine increased by 12-fold, 33-fold, and 3-fold, respectively, with coadministration of fluvoxamine. The C max and AUC of tizanidine increased by 7-fold and 10-fold, respectively, with coadministration of ciprofloxacin [see Contraindications ( 4 )]. There have been no clinical studies evaluating the effects of other CYP1A2 inhibitors on tizanidine [see Drug Interactions ( 7.2 )]. In vitro studies of cytochrome P450 isoenzymes using human liver microsomes indicate that neither tizanidine nor the major metabolites are likely to affect the metabolism of other drugs metabolized by cytochrome P450 isoenzymes. Oral Contraceptives No specific pharmacokinetic study was conducted to investigate interaction between oral contraceptives and tizanidine. Retrospective analysis of population pharmacokinetic data following single and multiple dose administration of 4 mg tizanidine, however, showed that women concurrently taking oral contraceptives had 50% lower clearance of tizanidine compared to women not on oral contraceptives [see Drug Interactions ( 7.3 )]. Acetaminophen Tizanidine delayed the T max of acetaminophen by 16 minutes. Acetaminophen did not affect the pharmacokinetics of tizanidine. Alcohol Alcohol increased the AUC and C max of tizanidine by approximately 20% and 15%, respectively [see Drug Interactions ( 7.4 )] ."],"indications_and_usage":["1 INDICATIONS AND USAGE Tizanidine is indicated for the treatment of spasticity in adults. Tizanidine is a central alpha-2-adrenergic agonist indicated for the treatment of spasticity. (1)"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypotension: monitor for signs and symptoms of hypotension, in particular in patients receiving concurrent antihypertensives; tizanidine should not be used with other α 2 -adrenergic agonists ( 5.1 , 7.5 ) Risk of liver injury: monitor ALTs; discontinue tizanidine if liver injury occurs ( 5.2 ) Sedation: Tizanidine may interfere with everyday activities; sedative effects of tizanidine, alcohol, and other central nervous system (CNS) depressants are additive ( 5.3 , 7.4 ) Hallucinations: consider discontinuation of tizanidine ( 5.4 ) 5.1 Hypotension Tizanidine is an α 2 -adrenergic agonist that can produce hypotension [see Adverse Reactions ( 6.1 ) and Drug Interactions ( 7.5 )] . Syncope has been reported in patients treated with tizanidine in the postmarketing setting. The risk of hypotension may be minimized by dose titration; monitoring for signs and symptoms of hypotension prior to dosage increase may minimize the risks associated with hypotension. In addition, patients moving from a supine to fixed upright position may be at increased risk for hypotension and orthostatic effects. Monitor for hypotension when tizanidine is used in patients receiving concurrent antihypertensive therapy. It is not recommended that tizanidine be used with other α 2 -adrenergic agonists. Clinically significant hypotension (decreases in both systolic and diastolic pressure) has been reported with concomitant administration of tizanidine and strong CYP1A2 inhibitors [see Clinical Pharmacology ( 12.3 )] . Therefore, concomitant use of tizanidine with strong CYP1A2 inhibitors is contraindicated [see Contraindications (4) and Drug Interactions ( 7.1 )]. 5.2 Liver Injury Tizanidine may cause hepatocellular liver injury. Liver function test abnormality and hepatotoxicity have been observed with tizanidine [see Adverse Reactions ( 6.1 , 6.2 )]. Monitoring of aminotransferase levels is recommended at baseline and 1 month after maximum dose is achieved, or if hepatic injury is suspected [see Dosage and Administration ( 2.1 ) and Use in Specific Populations ( 8.7 )] . 5.3 Sedation Tizanidine can cause sedation, which may interfere with everyday activity. In the multiple dose studies of tizanidine, the prevalence of patients with sedation peaked following the first week of titration and then remained stable for the duration of the maintenance phase of the study [see Adverse Reactions ( 6.1 )]. The CNS depressant effects of tizanidine with alcohol and other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants) may be additive [see Drug Interactions ( 7.4 )] . Monitor patients who take tizanidine with another CNS depressant for symptoms of excess sedation. 5.4 Hallucinosis / Psychotic-Like Symptoms Tizanidine use has been associated with hallucinations. Formed, visual hallucinations or delusions were reported in 5 of 170 patients (3%) in two North American controlled clinical studies. Most of the patients were aware that the events were unreal. One patient developed psychosis in association with the hallucinations. One patient among these 5 continued to have problems for at least 2 weeks following discontinuation of tizanidine. Hallucinations have also been reported with tizanidine use in the postmarketing setting. Consider discontinuing tizanidine in patients who develop hallucinations. 5.5 Hypersensitivity Reactions Tizanidine can cause anaphylaxis. Signs and symptoms of hypersensitivity, including respiratory compromise, urticaria, and angioedema of the throat and tongue, have been reported. Tizanidine is contraindicated in patients with a history of hypersensitivity reactions to tizanidine [see Contraindications ( 4 )]. 5.6 Withdrawal Adverse Reactions Tizanidine can cause withdrawal adverse reactions, which include rebound hypertension, tachycardia, and hypertonia. To minimize the risk of these reactions, particularly in patients who have been receiving high doses of tizanidine (20 to 28 mg daily) for long periods of time (9 weeks or more) or who may be on concomitant treatment with narcotics, the tizanidine dosage should be decreased slowly [see Dosage and Administration ( 2.5 )]."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Tizanidine was administered to mice for 78 weeks at oral doses up to 16 mg/kg/day, which is 2 times the maximum recommended human dose (MRHD) of 36 mg/day on a body surface area (mg/m 2 ) basis. Tizanidine was administered to rats for 104 weeks at oral doses up to 9 mg/kg/day, which is 2.5 times the MRHD on a mg/m 2 basis. There was no increase in tumors in either species. Mutagenesis Tizanidine was negative in in vitro (bacterial reverse mutation [Ames], mammalian gene mutation, and chromosomal aberration test in mammalian cells) and in vivo (bone marrow micronucleus, and cytogenetics) assay. Impairment of Fertility Oral administration of tizanidine to rats prior to and during mating and continuing during early pregnancy in females resulted in reduced fertility in male and female rats at doses of 30 and 10 mg/kg/day, respectively. No effect on fertility was observed at doses of 10 (male) and 3 (female) mg/kg/day, which are approximately 3 times and similar to the MRHD, respectively, on a mg/m 2 basis."],"adverse_reactions_table":["<table frame=\"box\" rules=\"all\" width=\"60%\"><caption>Table 1: Multiple Dose, Placebo-Controlled Studies&#x2014;Adverse Reactions Reported in &gt;2% of Patients Treated with Tizanidine Tablets and Incidence Greater than Placebo</caption><col align=\"left\" width=\"30%\"/><col align=\"center\" width=\"15%\"/><col align=\"center\" width=\"15%\"/><thead><tr><th valign=\"middle\">Adverse Reaction</th><th valign=\"bottom\">Placebo  N = 261  %</th><th valign=\"bottom\">Tizanidine Tablet  N = 264  %</th></tr></thead><tbody><tr><td valign=\"bottom\">Dry mouth</td><td valign=\"bottom\">10</td><td valign=\"bottom\">49</td></tr><tr><td align=\"left\" valign=\"bottom\">Somnolence</td><td valign=\"bottom\">10</td><td valign=\"bottom\">48</td></tr><tr><td align=\"left\" valign=\"bottom\">Asthenia<footnote/></td><td valign=\"bottom\">16</td><td valign=\"bottom\">41</td></tr><tr><td align=\"left\" valign=\"bottom\">Dizziness</td><td valign=\"bottom\">4</td><td valign=\"bottom\">16</td></tr><tr><td align=\"left\" valign=\"bottom\">UTI</td><td valign=\"bottom\">7</td><td valign=\"bottom\">10</td></tr><tr><td align=\"left\" valign=\"bottom\">Infection</td><td valign=\"bottom\">5</td><td valign=\"bottom\">6</td></tr><tr><td align=\"left\" valign=\"bottom\">Liver test abnormality</td><td valign=\"bottom\">2</td><td valign=\"bottom\">6</td></tr><tr><td align=\"left\" valign=\"bottom\">Constipation</td><td valign=\"bottom\">1</td><td valign=\"bottom\">4</td></tr><tr><td align=\"left\" valign=\"bottom\">Vomiting</td><td valign=\"bottom\">0</td><td valign=\"bottom\">3</td></tr><tr><td align=\"left\" valign=\"bottom\">Speech disorder</td><td valign=\"bottom\">0</td><td valign=\"bottom\">3</td></tr><tr><td align=\"left\" valign=\"bottom\">Amblyopia (blurred vision)</td><td valign=\"bottom\">&lt;1</td><td valign=\"bottom\">3</td></tr><tr><td align=\"left\" valign=\"bottom\">Urinary frequency</td><td valign=\"bottom\">2</td><td valign=\"bottom\">3</td></tr><tr><td align=\"left\" valign=\"bottom\">Flu syndrome</td><td valign=\"bottom\">2</td><td valign=\"bottom\">3</td></tr><tr><td align=\"left\" valign=\"bottom\">Dyskinesia</td><td valign=\"bottom\">0</td><td valign=\"bottom\">3</td></tr><tr><td align=\"left\" valign=\"bottom\">Nervousness</td><td valign=\"bottom\">&lt;1</td><td valign=\"bottom\">3</td></tr><tr><td align=\"left\" valign=\"bottom\">Pharyngitis</td><td valign=\"bottom\">1</td><td valign=\"bottom\">3</td></tr><tr><td align=\"left\" valign=\"bottom\">Rhinitis</td><td valign=\"bottom\">2</td><td valign=\"bottom\">3</td></tr></tbody></table>","<table frame=\"box\" rules=\"all\" width=\"80%\"><caption>Table 2: Single Dose, Placebo-Controlled Study&#x2014;Common Adverse Reactions Reported</caption><col align=\"left\" width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><thead><tr><th valign=\"middle\">Adverse Reaction</th><th valign=\"bottom\">Placebo  N = 48  %</th><th valign=\"bottom\">Tizanidine Tablet,  8mg, N = 45  %</th><th valign=\"bottom\">Tizanidine Tablet,  16 mg, N = 49  %</th></tr></thead><tbody><tr align=\"center\"><td align=\"left\" valign=\"bottom\">Somnolence</td><td valign=\"bottom\">31</td><td valign=\"bottom\">78</td><td valign=\"bottom\">92</td></tr><tr align=\"center\"><td align=\"left\" valign=\"bottom\">Dry mouth</td><td valign=\"bottom\">35</td><td valign=\"bottom\">76</td><td valign=\"bottom\">88</td></tr><tr align=\"center\"><td align=\"left\" valign=\"bottom\">Asthenia<footnote/></td><td valign=\"bottom\">40</td><td valign=\"bottom\">67</td><td valign=\"bottom\">78</td></tr><tr align=\"center\"><td align=\"left\" valign=\"bottom\">Dizziness</td><td valign=\"bottom\">4</td><td valign=\"bottom\">22</td><td valign=\"bottom\">45</td></tr><tr align=\"center\"><td align=\"left\" valign=\"bottom\">Hypotension</td><td valign=\"bottom\">0</td><td valign=\"bottom\">16</td><td valign=\"bottom\">33</td></tr><tr align=\"center\"><td align=\"left\" valign=\"bottom\">Bradycardia</td><td valign=\"bottom\">0</td><td valign=\"bottom\">2</td><td valign=\"bottom\">10</td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Serious Drug Interactions Advise patients they should not take tizanidine tablets if they are taking fluvoxamine or ciprofloxacin because of the increased risk of serious adverse reactions including severe lowering of blood pressure and sedation. Instruct patients to inform their healthcare providers when they start or stop taking any medication because of the risks associated with interaction between tizanidine and other medicines [see Contraindications (4) and Drug Interactions ( 7 )]. Tizanidine Tablets Dosing and Administration Tell patients to take tizanidine tablets exactly as prescribed (consistently either with or without food) and not to switch between tablets and capsules [see Dosage and Administration ( 2 )]. Inform patients that they should not take more tizanidine tablets than prescribed because of the risk of adverse events at single doses greater than 8 mg or total daily doses greater than 36 mg. Tell patients that they should not suddenly discontinue tizanidine tablets, because rebound hypertension and tachycardia may occur [see Warnings and Precautions ( 5.6 )]. Hypotension Warn patients that they may experience hypotension and to be careful when changing from a lying or sitting to a standing position [see Warnings and Precautions ( 5.1 )]. Sedation Tell patients that tizanidine tablets may cause them to become sedated or somnolent and they should be careful when performing activities that require alertness, such as driving a vehicle or operating machinery [see Warnings and Precautions ( 5.3 )]. Tell patients that the sedation may be additive when tizanidine tablets is taken in conjunction with drugs (baclofen, benzodiazepines) or substances (e.g., alcohol) that act as CNS depressants. Remind patients that if they depend on their spasticity to sustain posture and balance in locomotion, or whenever spasticity is utilized to obtain increased function, that tizanidine tablets decreases spasticity and caution should be used. Hypersensitivity Reactions Inform patients of the signs and symptoms of severe allergic reactions and instruct them to discontinue tizanidine tablets and seek immediate medical care should these signs and symptoms occur [see Warnings and Precautions ( 5.5 )] . APOTEX INC. Tizanidine Tablets, USP 2 mg and 4 mg Manufactured by Manufactured for Apotex Inc. Apotex Corp. Toronto, Ontario Weston, Florida Canada M9L 1T9 USA 33326 Rev. 8"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Monitoring of aminotransferase levels is recommended at baseline and 1 month after maximum dose is achieved. ( 2.1 ) Recommended starting dose: 2 mg by mouth every 6 to 8 hours, as needed, up to a maximum of 3 doses in 24 hours ( 2.2 ) Dosage can be increased by 2 mg to 4 mg per dose every 1 to 4 days; maximum total daily dosage is 36 mg ( 2.2 ) Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. These differences could result in a change in tolerability and control of symptoms. Consistent administration with respect to food is recommended. If substitution between dosage forms is necessary, take into consideration these pharmacokinetic differences. ( 2.2 , 2.6 , 12.3 ) Patients with renal impairment (creatinine clearance <25 mL/min) or hepatic impairment: use lower individual doses during titration.If higher doses are required, individual doses rather than dosing frequency should be increased. ( 2.3 , 2.4 ) To discontinue tizanidine tablets, decrease dose slowly to minimize the risk of withdrawal adverse reactions ( 2.5 ) 2.1 Recommended Evaluation and Testing Before and After Initiating Tizanidine Monitoring of aminotransferase levels is recommended at baseline and 1 month after maximum dose is achieved [see Warnings and Precautions ( 5.2 )]. 2.2 Recommended Dosage The recommended starting dose is 2 mg by mouth every 6 to 8 hours, as needed, to a maximum of three doses in 24 hours. Dosage can be gradually increased every 1 to 4 days by 2 mg to 4 mg at each dose based on clinical response and tolerability. The maximum total daily dosage is 36 mg. Single doses greater than 16 mg have not been studied. There are pharmacokinetic differences when administering tizanidine between the fed or fasted state [see Clinical Pharmacology ( 12.3 )] . Tizanidine may be taken with or without food; however, consistent administration with respect to food is recommended to reduce variability in tizanidine plasma exposure. Because of the short duration of therapeutic effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important. 2.3 Recommended Dosage in Patients with Renal Impairment I n patients with creatinine clearance < 25 mL/min, use lower individual doses during titration. If higher doses are required, the individual doses rather than dosing frequency should be increased [see Use in Specific Populations ( 8.6 ) and Clinical Pharmacology ( 12.3 )] . 2.4 Recommended Dosage in Patients with Hepatic Impairment I n patients with hepatic impairment, use lower individual doses during titration. If higher doses are required, individual doses rather than dosing frequency should be increased [see Use in Specific Populations ( 8.7 ) and Clinical Pharmacology ( 12.3 )]. 2.5 Discontinuation of Tizanidine Tablets When discontinuing tizanidine tablets, particularly in patients who have been receiving high doses for long periods or who may be on concomitant treatment with narcotics, decrease the dosage by 2 mg to 4 mg per day to minimize the risk of withdrawal adverse reactions [see Drug Abuse and Dependence ( 9.3 )]. 2.6 Switching Between With/Without Food and Different Tizanidine Dosage Forms There are pharmacokinetic differences when: 1) switching between administration of tizanidine tablets with or without food 2) switching between dosage forms if being administered with food. If these situations occur, monitor patients for therapeutic effect or adverse reactions [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )]."],"drug_abuse_and_dependence":["9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance Tizanidine tablets contain tizanidine, which is not a controlled substance. 9.2 Abuse Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Abuse potential was not evaluated in human studies. Rats were able to distinguish tizanidine from saline in a standard discrimination paradigm, after training, but failed to generalize the effects of morphine, cocaine, diazepam, or phenobarbital to tizanidine. 9.3 Dependence Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Tizanidine is closely related to clonidine, which is often abused in combination with narcotics and is known to cause symptoms of rebound upon abrupt withdrawal. Cases of rebound symptoms on sudden withdrawal of tizanidine have been reported. The case reports suggest that these patients were also misusing narcotics. Withdrawal symptoms included hypertension, tachycardia, hypertonia, tremor, and anxiety. Withdrawal symptoms are more likely to occur in cases where high doses are used, especially for prolonged periods, or with concomitant use of narcotics. If therapy needs to be discontinued, the dose should be decreased slowly to minimize the risk of withdrawal symptoms [see Dosage and Administration ( 2.5 )]. Monkeys were shown to self-administer tizanidine in a dose-dependent manner, and abrupt cessation of tizanidine produced transient signs of withdrawal at doses > 35 times the maximum recommended human dose on a mg/m 2 basis. These transient withdrawal signs (increased locomotion, body twitching, and aversive behavior toward the observer) were not reversed by naloxone administration."],"spl_product_data_elements":["tizanidine tizanidine TIZANIDINE HYDROCHLORIDE Tizanidine ANHYDROUS LACTOSE SILICON DIOXIDE MICROCRYSTALLINE CELLULOSE STEARIC ACID APO;TI;2 tizanidine tizanidine TIZANIDINE HYDROCHLORIDE Tizanidine ANHYDROUS LACTOSE SILICON DIOXIDE MICROCRYSTALLINE CELLULOSE STEARIC ACID APO;TI;4 chemical-structure figure-1.jpg figure-2.jpg figure-3.jpg tizanidine-label-2mg.jpg tizanidine-label-4mg-150s.jpg"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets 2 mg - white to off-white, round, scored tablets, imprinted “APO” over “TI-2” on one side and plain with a bisect score on the other side. 4 mg- white to off-white, round, scored tablets, imprinted “APO” over “TI-4” on one side and plain with a quadrisect score on the other side. Tablets 2 mg and 4 mg (3)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data, may cause fetal harm ( 8.1 ) Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased four-fold ( 8.5 ) 8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with use of tizanidine tablets in pregnant women. In animal studies, administration of tizanidine during pregnancy resulted in developmental toxicity (embryofetal and postnatal offspring mortality and growth deficits) at doses less than those used clinically, which were not associated with maternal toxicity (see Animal Data ). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Animal Data Oral administration of tizanidine (0.3 to 100 mg/kg/day) to pregnant rats during the period of organogenesis resulted in embryofetal and postnatal offspring mortality and reductions in body weight at doses of 30 mg/kg/day and above. Maternal toxicity was observed at the highest dose tested. The no-effect dose for embryofetal developmental toxicity in rats (3 mg/kg/day) is similar to the maximum recommended human dose (MRHD) of 36 mg/day on a body surface area (mg/m 2 ) basis. Oral administration of tizanidine (1 to 100 mg/kg/day) to pregnant rabbits during the period of organogenesis resulted in embryofetal and postnatal offspring mortality at all doses. Maternal toxicity was observed at the highest dose tested. Oral administration of tizanidine (10 and 30 mg/kg/day) during the perinatal period of pregnancy (2 to 6 days prior to delivery) resulted in increased postnatal offspring mortality at both doses. A no-effect dose for embryofetal developmental toxicity in rabbit was not identified. The lowest dose tested (1 mg/kg/day) is less than the MRHD on a mg/m 2 basis. In a pre- and postnatal development study in rats, oral administration of tizanidine (3 to 30 mg/kg/day) resulted in increased postnatal offspring mortality. A no-effect dose for pre- and postnatal developmental toxicity was not identified. The lowest dose tested (3 mg/kg/day) is similar to the MRHD on a mg/m 2 basis, respectively. 8.2 Lactation Risk Summary There are no data on the presence of tizanidine in human milk, the effects on the breastfed infant, or the effects on human milk production. Animal studies have reported the presence of tizanidine in the milk of lactating animals. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tizanidine and any potential adverse effects on the breastfed infant from tizanidine or from the underlying maternal condition. 8.3 Females and Males of Reproductive Potential There are no adequate and well-controlled studies in humans on the effect of tizanidine on female or male reproductive potential. Oral administration of tizanidine to male and female rats resulted in adverse effects on fertility [see Nonclinical Toxicology (13.1) ]. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Juvenile Animal Toxicity Data Oral administration of tizanidine (0, 1, 3, and 10 mg/kg/day) to juvenile rats from postnatal day (PND) 7 through PND 70 resulted in delayed sexual maturation in males at all doses, reduced body weight gain, delayed sexual maturation in females, and bilateral corneal crystals at the mid and high doses. Corneal crystals were still observed at the mid and high doses after a three-week recovery period. Neurobehavioral deficits were observed on a learning and memory task at the high dose. A no-effect dose for adverse effects on postnatal development not identified. 8.5 Geriatric Use Tizanidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Clinical studies of tizanidine tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Pharmacokinetic data showed that younger subjects cleared tizanidine faster than the elderly subjects [see Clinical Pharmacology ( 12.3 )] . In elderly patients with renal insufficiency (creatinine clearance < 25 mL/min), tizanidine clearance is reduced compared to healthy elderly subjects; this would be expected to lead to a longer duration of clinical effect. During titration, the individual doses should be reduced. If higher doses are required, individual doses rather than dosing frequency should be increased. Monitor elderly patients because they may have an increased risk for adverse reactions associated with tizanidine tablets. 8.6 Renal Impairment In patients with renal insufficiency (creatinine clearance < 25 mL/min), clearance of tizanidine was reduced [see Clinical Pharmacology ( 12.3 )] . In these patients, dosage reduction is recommended [see Dosage and Administration ( 2.3 )]. Because the risk of adverse reactions to tizanidine tablets may be greater in patients with impaired renal function, monitor these patients closely for the onset or increase in severity of common adverse reactions [see Adverse Reactions ( 6.1 )] . 8.7 Hepatic Impairment Tizanidine tablets should be used with caution in patients with hepatic impairment. The influence of hepatic impairment on the pharmacokinetics of tizanidine has not been evaluated. Because tizanidine is extensively metabolized in the liver, hepatic impairment would be expected to have significant effects on pharmacokinetics of tizanidine [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )]. In patients with hepatic impairment, dosage reduction is recommended [see Dosage and Administration ( 2.4 )]."],"information_for_patients_table":["<table frame=\"void\" width=\"30%\"><col width=\"25%\"/><col width=\"20%\"/><tbody><tr styleCode=\"toprule\"><td><content styleCode=\"bold\">Manufactured by</content></td><td><content styleCode=\"bold\">Manufactured for</content></td></tr><tr><td>Apotex Inc.</td><td>Apotex Corp.</td></tr><tr><td>Toronto, Ontario</td><td>Weston, Florida</td></tr><tr><td>Canada M9L 1T9</td><td>USA 33326</td></tr></tbody></table>"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 2 MG BOTTLE LABEL APOTEX CORP. NDC 60505-0251-3 Tizanidine Tablets, USP Equivalent to 2 mg tizanidine 2 mg Rx Only 100 Tablets","PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 4 MG LABEL APOTEX CORP. NDC 60505-0252-3 Tizanidine Tablets, USP Equivalent to 4 mg tizanidine 4 mg Rx Only 100 Tablets"]},"tags":[{"label":"Central alpha-2 Adrenergic Agonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Nischarin","category":"target"},{"label":"NISCH","category":"gene"},{"label":"ADRA2A","category":"gene"},{"label":"ADRA2C","category":"gene"},{"label":"M03BX02","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Muscle Spasticity of Cerebral Origin","category":"indication"},{"label":"Muscle spasticity of spinal origin","category":"indication"},{"label":"Spasticity","category":"indication"},{"label":"Legacy Pharma Usa","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Agonists","category":"pharmacology"},{"label":"Adrenergic alpha-2 Receptor Agonists","category":"pharmacology"},{"label":"Adrenergic alpha-Agonists","category":"pharmacology"},{"label":"Analgesics","category":"pharmacology"},{"label":"Anticonvulsants","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Muscle Relaxants, Central","category":"pharmacology"},{"label":"Neuromuscular Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"3093 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"2980 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"2888 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"2762 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"2587 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"2267 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1858 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"1855 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1549 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"1546 reports"}],"drugInteractions":[{"url":"/drug/estradiol","drug":"estradiol","action":"Monitor closely","effect":"May interact with Estradiol","source":"DrugCentral","drugSlug":"estradiol"},{"url":"/drug/ethinylestradiol","drug":"ethinylestradiol","action":"Monitor closely","effect":"May interact with Ethinyl Estradiol","source":"DrugCentral","drugSlug":"ethinylestradiol"},{"url":"/drug/etonogestrel","drug":"etonogestrel","action":"Monitor closely","effect":"May interact with Etonogestrel","source":"DrugCentral","drugSlug":"etonogestrel"},{"url":"/drug/levonorgestrel","drug":"levonorgestrel","action":"Monitor closely","effect":"May interact with Levonorgestrel","source":"DrugCentral","drugSlug":"levonorgestrel"},{"url":"/drug/norethisterone","drug":"norethisterone","action":"Monitor closely","effect":"May interact with Norethindrone","source":"DrugCentral","drugSlug":"norethisterone"},{"url":"/drug/saquinavir","drug":"saquinavir","action":"Monitor closely","effect":"May interact with Saquinavir","source":"DrugCentral","drugSlug":"saquinavir"},{"url":"/drug/valaciclovir","drug":"valaciclovir","action":"Monitor closely","effect":"May interact with Valacyclovir Hydrochloride","source":"DrugCentral","drugSlug":"valaciclovir"},{"url":"/drug/verapamil","drug":"verapamil","action":"Avoid combination","effect":"May interact with Verapamil","source":"DrugCentral","drugSlug":"verapamil"},{"url":"/drug/zileuton","drug":"zileuton","action":"Avoid combination","effect":"May interact with Zileuton","source":"DrugCentral","drugSlug":"zileuton"}],"commonSideEffects":[{"effect":"Somnolence","drugRate":"92%","severity":"serious","_validated":true},{"effect":"Dry mouth","drugRate":"88%","severity":"serious","_validated":true},{"effect":"Asthenia","drugRate":"78%","severity":"serious","_validated":true},{"effect":"Dizziness","drugRate":"76%","severity":"serious","_validated":true},{"effect":"Hypotension","drugRate":"45%","severity":"serious","_validated":true},{"effect":"Bradycardia","drugRate":"33%","severity":"serious","_validated":true},{"effect":"Fatigue","drugRate":"reported","severity":"unknown"},{"effect":"Muscle spasms","drugRate":"reported","severity":"unknown"},{"effect":"Hallucinations","drugRate":"reported","severity":"unknown"},{"effect":"Liver function test abnormality","drugRate":"reported","severity":"unknown"},{"effect":"Hepatotoxicity","drugRate":"reported","severity":"unknown"},{"effect":"Convulsion","drugRate":"reported","severity":"unknown"},{"effect":"Depression","drugRate":"reported","severity":"unknown"},{"effect":"Arthralgia","drugRate":"reported","severity":"unknown"},{"effect":"Paresthesia","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Tremor","drugRate":"reported","severity":"unknown"},{"effect":"Anaphylactic Reaction","drugRate":"reported","severity":"unknown"},{"effect":"Exfoliative Dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"Ventricular Tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Hepatitis","drugRate":"reported","severity":"unknown"},{"effect":"Stevens Johnson Syndrome","drugRate":"reported","severity":"unknown"}],"contraindications":["Bradycardia","Hepatic failure","Kidney disease","Low blood pressure","Psychotic disorder"],"specialPopulations":{"Pregnancy":"Tizanidine has not been studied in pregnant women. It should be given to pregnant women only if the benefit outweighs the risk to the unborn fetus. Reproduction studies performed in rats and rabbits did not show evidence of teratogenicity, but increased gestation duration, prenatal and postnatal pup loss, and developmental retardation occurred at certain doses.","Geriatric use":"Tizanidine should be used with caution in elderly patients because clearance is decreased four-fold.","Paediatric use":"There are no adequate and well-controlled studies to document the safety and efficacy of tizanidine in children.","Renal impairment":"The risk of adverse reactions to this drug may be greater in patients with impaired renal function."}},"trials":[],"aliases":[],"company":"Legacy Pharma Usa","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1361/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$50","description":"TIZANIDINE HCL 2 MG CAPSULE","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TIZANIDINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:15:03.084988+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:15:08.447635+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:15:02.158630+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TIZANIDINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:15:08.960893+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:15:00.747743+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:15:00.747779+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:15:10.466018+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Adrenergic receptor alpha-2 agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:15:10.009255+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200329/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:15:09.661729+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA076533","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:15:00.747783+00:00"}},"allNames":"zanaflex","offLabel":[],"synonyms":["DS 103-282","tizanidine","tizanidine hydrochloride","tizanidine HCl","AN021","DS103-282"],"timeline":[{"date":"1996-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ACORDA to Legacy Pharma Usa"},{"date":"1996-11-27","type":"positive","source":"DrugCentral","milestone":"FDA approval (Acorda)"},{"date":"2000-02-04","type":"positive","source":"FDA Orange Book","milestone":"Zanaflex approved — EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2003-04-09","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 5 manufacturers approved"},{"date":"2024-12-12","type":"positive","source":"FDA Orange Book","milestone":"Ontralfy approved — EQ 2MG BASE/5ML"}],"aiSummary":"Zanaflex (Tizanidine) is a central alpha-2 adrenergic agonist small molecule developed by ACORDA and currently owned by Legacy Pharma Usa. It targets the Nischarin protein and was FDA approved in 1996 for treating muscle spasticity of cerebral and spinal origin. Zanaflex is off-patent with 23 generic manufacturers, offering a commercial alternative to branded options. Key safety considerations include its short half-life of 2.4 hours and bioavailability of 21%. As an off-patent medication, Zanaflex is widely available in the market.","approvals":[{"date":"1996-11-27","orphan":true,"company":"ACORDA","regulator":"FDA"}],"brandName":"Zanaflex","ecosystem":[{"indication":"Muscle Spasticity of Cerebral Origin","otherDrugs":[{"name":"baclofen","slug":"baclofen","company":""},{"name":"dantrolene","slug":"dantrolene","company":"Par Sterile Products"}],"globalPrevalence":null},{"indication":"Muscle spasticity of spinal origin","otherDrugs":[{"name":"baclofen","slug":"baclofen","company":""},{"name":"dantrolene","slug":"dantrolene","company":"Par Sterile Products"}],"globalPrevalence":null},{"indication":"Spasticity","otherDrugs":[{"name":"caffeine","slug":"caffeine","company":"Novartis"},{"name":"carisoprodol","slug":"carisoprodol","company":"Meda Pharms"},{"name":"chlorphenesin carbamate","slug":"chlorphenesin-carbamate","company":"Pharmacia And Upjohn"},{"name":"chlorzoxazone","slug":"chlorzoxazone","company":"Janssen R And D"}],"globalPrevalence":null}],"mechanism":{"target":"Nischarin","novelty":"Follow-on","targets":[{"gene":"NISCH","source":"DrugCentral","target":"Nischarin","protein":"Nischarin"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"}],"moaClass":"Adrenergic alpha2-Agonists","modality":"Small Molecule","drugClass":"Central alpha-2 Adrenergic Agonist","explanation":"","oneSentence":"","technicalDetail":"Tizanidine acts as a selective alpha-2 adrenergic receptor agonist, activating the imidazoline receptor to inhibit the release of excitatory neurotransmitters, thereby reducing muscle spasticity."},"commercial":{"launchDate":"1996","_launchSource":"DrugCentral (FDA 1996-11-27, ACORDA)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2683","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TIZANIDINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TIZANIDINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:56:52.367837","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:15:13.688709+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"baclofen","drugSlug":"baclofen","fdaApproval":"1977-11-22","patentExpiry":"Sep 8, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cyclobenzaprine","drugSlug":"cyclobenzaprine","fdaApproval":"1977-08-26","patentExpiry":"Mar 14, 2034","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"tizanidine","indications":{"approved":[{"name":"Muscle Spasticity of Cerebral Origin","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Muscle spasticity of spinal origin","source":"DrugCentral","snomedId":416830008,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Spasticity","source":"DrugCentral","snomedId":221360009,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[],"pipeline":[]},"currentOwner":"Legacy Pharma Usa","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"baclofen","brandName":"baclofen","genericName":"baclofen","approvalYear":"1977","relationship":"same-class"},{"drugId":"cyclobenzaprine","brandName":"cyclobenzaprine","genericName":"cyclobenzaprine","approvalYear":"1977","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05789173","phase":"EARLY_PHASE1","title":"Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-10-06","conditions":["Drug-Drug Interaction"],"enrollment":60,"completionDate":"2026-04-15"},{"nctId":"NCT05488847","phase":"PHASE4","title":"Opioid-Free Pain Protocol After Shoulder Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henry Ford Health System","startDate":"2022-06-25","conditions":["Shoulder Arthropathy","Shoulder Pain"],"enrollment":83,"completionDate":"2026-09-01"},{"nctId":"NCT07382921","phase":"NA","title":"Efficacy and Safety of Pregabalin/Tizanidine vs. Pregabalin in Patients With Fibromyalgia","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-01-30","conditions":["Fibromyalgia","Pregabalin","Pain"],"enrollment":164,"completionDate":"2026-08"},{"nctId":"NCT07022353","phase":"NA","title":"Bi-level Erector Spinae Plane Block and Pre-emptive Oral Tizanidine for Analgesia After Mastectomy Surgery","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2025-07-15","conditions":["Mastectomy Patient"],"enrollment":90,"completionDate":"2025-12-30"},{"nctId":"NCT06863662","phase":"PHASE3","title":"Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2024-09-18","conditions":["Acute Low-back Pain","Muscle Spasm; Back Pain"],"enrollment":136,"completionDate":"2025-12-01"},{"nctId":"NCT07310628","phase":"PHASE4","title":"Comparison of Analgesic Efficacy of Intrathecal Levobupivacaine With and Without Oral Tizanidine in Lower Limb Surgeries: A Prospective Randomized Study","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2022-08-20","conditions":["Tizanididne","Levobupicaine","Lower Limb Surgery","Pain, Chronic"],"enrollment":64,"completionDate":"2025-08-20"},{"nctId":"NCT07309354","phase":"NA","title":"Tizanidine and Acoustic Reflex","status":"RECRUITING","sponsor":"Uşak University","startDate":"2025-07-15","conditions":["Reflex, Acoustic","Hearing"],"enrollment":45,"completionDate":"2026-03-15"},{"nctId":"NCT06258785","phase":"PHASE3","title":"Effect of Tizanidine on Postoperative Urinary Retention After Sacrospinous Suspension","status":"COMPLETED","sponsor":"Endeavor Health","startDate":"2024-09-17","conditions":["Postoperative Urinary Retention","Sacrospinous Vaginal Vault Suspension","Reconstructive Pelvic Surgery"],"enrollment":20,"completionDate":"2025-10-24"},{"nctId":"NCT07025187","phase":"NA","title":"the Effect of Integrated Neuomuscular Inhibition Technique on Adult Females With Cervicogenic Headache","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2025-06-16","conditions":["Cervicogenic Headache"],"enrollment":40,"completionDate":"2025-11-01"},{"nctId":"NCT06027099","phase":"PHASE3","title":"CARES-Spine (Comprehensive Analgesic, Recovery, and Education Support for Spine Surgery) Trial","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-12-05","conditions":["Chronic Pain","Back Pain","Neck Pain","Opioid Misuse"],"enrollment":375,"completionDate":"2028-07"},{"nctId":"NCT06382662","phase":"PHASE4","title":"Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition","status":"COMPLETED","sponsor":"Primus Pharmaceuticals","startDate":"2024-04-29","conditions":["Cognitive Impairment"],"enrollment":20,"completionDate":"2025-03-06"},{"nctId":"NCT06666673","phase":"EARLY_PHASE1","title":"Effect of Neural Constraints on Movement in Stroke","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-08-23","conditions":["Stroke"],"enrollment":64,"completionDate":"2029-07-31"},{"nctId":"NCT04429347","phase":"PHASE2","title":"Gabapentin and Tizanidine for Insomnia in Chronic Pain","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-07-29","conditions":["Insomnia Due to Medical Condition","Chronic Pain"],"enrollment":9,"completionDate":"2024-12-01"},{"nctId":"NCT05484349","phase":"PHASE3","title":"TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME）","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-06-01","conditions":["Migraine Without Aura","Migraine With Aura"],"enrollment":189,"completionDate":"2025-12-25"},{"nctId":"NCT06274021","phase":"EARLY_PHASE1","title":"Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury","status":"RECRUITING","sponsor":"University of Mississippi Medical Center","startDate":"2024-03-01","conditions":["Spinal Cord Injuries","Spinal Cord Injury","Spinal Cord Injury Cervical","Spinal Cord Injury Thoracic"],"enrollment":16,"completionDate":"2025-12-31"},{"nctId":"NCT06303076","phase":"PHASE4","title":"Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2024-09","conditions":["Depressive Disorder, Major"],"enrollment":90,"completionDate":"2026-12"},{"nctId":"NCT04990804","phase":"PHASE4","title":"Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-08-01","conditions":["Opioid Use","Spinal Diseases","Surgery--Complications","Surgery","Postoperative Pain"],"enrollment":8,"completionDate":"2022-02-01"},{"nctId":"NCT05852093","phase":"EARLY_PHASE1","title":"Clinical Study on the Effect of Tizanidine on the Function and Pain of Patients After Shoulder Arthroscopy","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-06-01","conditions":["Rotator Cuff Tears"],"enrollment":100,"completionDate":"2027-06-01"},{"nctId":"NCT01839279","phase":"PHASE2","title":"A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2013-04","conditions":["Spasticity"],"enrollment":136,"completionDate":"2014-05"},{"nctId":"NCT04574791","phase":"NA","title":"Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty","status":"UNKNOWN","sponsor":"Rothman Institute Orthopaedics","startDate":"2020-09-03","conditions":["Pain, Postoperative"],"enrollment":240,"completionDate":"2021-09-30"},{"nctId":"NCT03068897","phase":"PHASE4","title":"Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2017-05-03","conditions":["Low Back Pain"],"enrollment":320,"completionDate":"2018-10-11"},{"nctId":"NCT04003350","phase":"NA","title":"The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Rothman Institute Orthopaedics","startDate":"2017-12-21","conditions":["Osteo Arthritis Knee"],"enrollment":216,"completionDate":"2019-03-15"},{"nctId":"NCT02887534","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of SPARC1401 in Acute Low Back Pain","status":"WITHDRAWN","sponsor":"Sun Pharma Advanced Research Company Limited","startDate":"2016-11","conditions":["Acute Muscle Pain"],"enrollment":0,"completionDate":"2017-12"},{"nctId":"NCT01788969","phase":"PHASE1","title":"Serotonergic Modulation of Motor Function in Subacute and Chronic SCI","status":"UNKNOWN","sponsor":"Shirley Ryan AbilityLab","startDate":"2005-06","conditions":["Spinal Cord Injury"],"enrollment":42,"completionDate":"2019-12"},{"nctId":"NCT01753882","phase":"PHASE1","title":"Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury (SCI)","status":"UNKNOWN","sponsor":"Shirley Ryan AbilityLab","startDate":"2012-02","conditions":["Spinal Cord Injury"],"enrollment":88,"completionDate":"2020-07"},{"nctId":"NCT02403687","phase":"","title":"Prospective Analgesic Compound Efficacy (PACE) Study","status":"COMPLETED","sponsor":"Express Specialty Pharmacy","startDate":"2015-06","conditions":["Arthritis","Tendonitis","Gout","Radiculopathy","Muscle Spasms","Synovitis","Migraine","Headache"],"enrollment":300,"completionDate":"2017-02"},{"nctId":"NCT02934061","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Tizaspray® Versus Sirdalud®, in Patients With Acute Low Back Pain","status":"COMPLETED","sponsor":"MDM S.p.A.","startDate":"2016-10","conditions":["Low Back Pain"],"enrollment":117,"completionDate":"2017-02"},{"nctId":"NCT02508805","phase":"PHASE3","title":"Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-05","conditions":["Vertebrogenic Radiculopathy L5, S1"],"enrollment":100,"completionDate":"2015-11"},{"nctId":"NCT01844674","phase":"PHASE1","title":"A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09-02","conditions":["Malignant Melanoma, Neoplasms"],"enrollment":18,"completionDate":"2014-08-26"},{"nctId":"NCT02725359","phase":"PHASE4","title":"Tizanidine and Superficial Cervical Block on Pain After Thyroidectomy","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2016-04","conditions":["Thyroidectomy"],"enrollment":60,"completionDate":"2016-12"},{"nctId":"NCT00047580","phase":"PHASE3","title":"Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.","status":"COMPLETED","sponsor":"Elan Pharmaceuticals","startDate":"2002-06","conditions":["Multiple Sclerosis","Muscle Spasticity","Spinal Cord Injury","Stroke"],"enrollment":120,"completionDate":"2002-09"},{"nctId":"NCT01979510","phase":"PHASE3","title":"Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11","conditions":["Low Back Pain"],"enrollment":0,"completionDate":"2014-05"},{"nctId":"NCT02016443","phase":"PHASE4","title":"Tizanidine and Pain After Herniorrhaphy","status":"COMPLETED","sponsor":"Diskapi Teaching and Research Hospital","startDate":"2013-11","conditions":["Unilateral Inguinal Hernia"],"enrollment":30,"completionDate":"2014-06"},{"nctId":"NCT01405950","phase":"PHASE1","title":"Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy","status":"TERMINATED","sponsor":"Acorda Therapeutics","startDate":"2011-05","conditions":["Spasticity Due to Cerebral Palsy"],"enrollment":10,"completionDate":"2012-03"},{"nctId":"NCT01068847","phase":"PHASE1","title":"Drug Discrimination in Methadone-Maintained Humans Study 3","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2010-02","conditions":["Drug Dependence"],"enrollment":9,"completionDate":"2012-11"},{"nctId":"NCT01146028","phase":"PHASE1","title":"Bioequivalence Study of Tizanidine HCl Tablets 4 mg of Dr.Reddys Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2001-09","conditions":["Healthy"],"enrollment":42,"completionDate":"2001-11"},{"nctId":"NCT01065987","phase":"PHASE1","title":"Bioequivalence Study of Tizanidine HCl 4mg Tablets of Dr.Reddy's Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2001-09","conditions":["Healthy"],"enrollment":24,"completionDate":"2001-11"},{"nctId":"NCT00464958","phase":"PHASE1,PHASE2","title":"One Year Extension Study To Protocol C2/5/TZ:MS-05","status":"TERMINATED","sponsor":"Teva GTC","startDate":"2008-01","conditions":["Spasticity","Multiple Sclerosis"],"enrollment":10,"completionDate":"2008-12"},{"nctId":"NCT00358293","phase":"PHASE1,PHASE2","title":"Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity","status":"COMPLETED","sponsor":"Teva GTC","startDate":"2006-12","conditions":["Muscle Spasticity"],"enrollment":20,"completionDate":"2007-02"},{"nctId":"NCT00287157","phase":"PHASE1","title":"Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)","status":"COMPLETED","sponsor":"Teva GTC","startDate":"2006-12","conditions":["Traumatic Brain Injury"],"enrollment":5,"completionDate":"2007-05"},{"nctId":"NCT00430196","phase":"PHASE4","title":"BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2003-12","conditions":["Upper Limb Spasticity"],"enrollment":135,"completionDate":"2006-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Tablet","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"TIZANIDINE HYDROCHLORIDE"},{"form":"CAPSULE","route":"ORAL","productName":"Tizanidine"},{"form":"CAPSULE","route":"ORAL","productName":"Tizanidine HCL"},{"form":"CAPSULE","route":"ORAL","productName":"Tizanidine Hydrochloride"},{"form":"CAPSULE","route":"ORAL","productName":"Tizanidine hydrochloride"},{"form":"CAPSULE","route":"ORAL","productName":"Tizanidne hydrochloride"},{"form":"CAPSULE","route":"ORAL","productName":"tizanidine hydrochloride"},{"form":"CAPSULE","route":"ORAL","productName":"ZANAFLEX"},{"form":"CAPSULE","route":"ORAL","productName":"Zanaflex"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"Tizanidine Hydrochloride"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"Zanaflex"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"tizanidine hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"TIZANDINE"},{"form":"TABLET","route":"ORAL","productName":"TIZANIDINE"},{"form":"TABLET","route":"ORAL","productName":"TIZANIDINE HYDROCHLORIDE"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148492","MMSL":"22951","NDDF":"006021","UNII":"6AI06C00GW","VUID":"4021025","CHEBI":"CHEBI:63629","VANDF":"4021025","INN_ID":"4697","RXNORM":"236460","UMLSCUI":"C0146011","chemblId":"CHEMBL1200329","ChEMBL_ID":"CHEMBL1079","KEGG_DRUG":"D00776","DRUGBANK_ID":"DB00697","PUBCHEM_CID":"5487","SNOMEDCT_US":"108461005","IUPHAR_LIGAND_ID":"7308","SECONDARY_CAS_RN":"64461-82-1","MESH_SUPPLEMENTAL_RECORD_UI":"C023754"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1996-","companyName":"Acorda","relationship":"Original Developer"},{"period":"present","companyName":"Legacy Pharma Usa","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.4 hours","clearance":"11.0 mL/min/kg","bioavailability":"21%","fractionUnbound":"0.7%","volumeOfDistribution":"2.4 L/kg"},"publicationCount":646,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"M03BX02","allCodes":["M03BX02"]},"biosimilarFilings":[],"originalDeveloper":"Acorda","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":23,"_genericFilersChecked":true,"genericManufacturerList":["Alembic","Alkem Labs Ltd","Ani Pharms","Apotex","Apotex Inc","Aurobindo Pharma Ltd","Aurobindo Pharma Usa","Cadila","Cadila Pharms Ltd","Chartwell Rx","Dr Reddys Labs Inc","Epic Pharma Llc","Ingenus Pharms Llc","Jubilant Generics","Oxford Pharms","Ph Health","Pharmobedient","Rising","Rubicon Research","Senores Pharms","Sun Pharm Inds Inc","Unichem Labs Ltd","Zydus Pharms"],"status":"approved","companyName":"Legacy Pharma Usa","companyId":"legacy-pharma-usa","modality":"Small molecule","firstApprovalDate":"1996","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-11-27T00:00:00.000Z","mah":"ACORDA","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-11-28T00:00:00.000Z","mah":"UNICHEM LABS LTD","brand_name_local":null,"application_number":"ANDA091283"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-12-14T00:00:00.000Z","mah":"SUN PHARM INDS INC","brand_name_local":null,"application_number":"ANDA076416"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-03-09T00:00:00.000Z","mah":"CADILA","brand_name_local":null,"application_number":"ANDA208187"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-05-27T00:00:00.000Z","mah":"RUBICON RESEARCH","brand_name_local":null,"application_number":"ANDA213798"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-05-27T00:00:00.000Z","mah":"INGENUS PHARMS LLC","brand_name_local":null,"application_number":"ANDA210267"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":6,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:15:13.688709+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}